Tag archive for ‘Perrigo’
Nir Eyal On Tuesday, February 28th, 2017

Perrigo shares down 10% after company reports loss, sells Tysabri Drug Royalties

  Perrigo announced on Monday that it had signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to RPI Finance More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
News Brief On Wednesday, November 25th, 2015

Mylan, Bruised by Failed Perrigo Bid, Set for Face-Off on Assets

Mylan NV, bruised by its acrimonious and ultimately unsuccessful bid to buy Perrigo Co., is likely to find itself now competing with the drugmaker for other assets. Both companies may look to buy Impax More...

Perrigo buys Crohn’s disease drug for $380 million

  Perrigo will acquire Entocort (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals within the US from AstraZeneca plc for $380 million. Entocort, a gastroenterology More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
Jewish Business News On Friday, November 13th, 2015

Mylan’s Hostile Bid For Drug Giant Perrigo Failed

  Mylan N.V. (NASDAQ: MYL; TASE) today announced that its offer to acquire all of the issued and to be issued share capital of Perrigo Company plc (NYSE: PRGO; TASE) has lapsed. Perrigo ordinary shares, More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
News Brief On Friday, November 13th, 2015

Mylan’s hostile bid for Ireland-based drugs giant Perrigo likely to fail

    If confirmed, the outcome would represent a major victory for Perrigo’s defiant Chief Executive Joseph Papa, and a bitter blow to Mylan’s Executive Chairman Robert Coury, who More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
News Brief On Thursday, November 12th, 2015

Mylan-targeted Perrigo held merger talks with Endo -sources

Perrigo Company Plc, the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV, held unsuccessful talks to acquire Endo International Plc in an all-stock deal, according More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
Niva Goldberg On Wednesday, November 4th, 2015

Mylan receives US FTC Clearance to buy Perrigo

Under the settlement agreement with the Federal Trade Commission, subject to final approval, Mylan NV has agreed to sell the rights and assets related to seven generic drugs to secure regulatory approval More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
News Brief On Tuesday, November 3rd, 2015

Why Mylan is taking its Perrigo pursuit to Tel Aviv’s stock exchange

Shares in the U.S. generic drugmaker Mylan will begin trading on the Tel Aviv Stock Exchange Wednesday, the TASE said Monday. The move comes after Mylan last week won an Israeli court ruling rejecting Perrigo’s More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
Gali Raz On Friday, October 30th, 2015

U.S. Court Denies Perrigo’s Attempt to Block Mylan’s Takeover Bid

Mylan N.V., which made a hostile takeover bid for Perrigo Co., said Friday that a U.S. District court denied Perrigo’s attempt to block the potential closing of Mylan’s proposed offer before shareholders. The More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
Niva Goldberg On Thursday, October 22nd, 2015

Perrigo Taking Actions To Fend off Mylan, Deliver Shareholder Value Far Superior To Mylan Offer

Perrigo, which is the target of a hostile takeover bid by Mylan, said Thursday that it would reduce its workforce by approximately 800 employees, or approximately 6 percent of its current global More...

Wordpress site Developed by Fixing WordPress Problems